Skip to Content
New To Chronic Myeloid Leukemia? Get Information Today >>

Medications for Microscopic polyangiitis

Drugs associated with Microscopic polyangiitis

The following drugs and medications are in some way related to, or used in the treatment of this condition.

What is Microscopic polyangiitis: Microscopic polyangiitis (MPA) is an inflammation of the medium and small vessel walls that can affect different parts of the body including (but not limited to) the kidneys, lungs, sinuses, nerves and skin.

Drug name Rx / OTC Pregnancy CSA Alcohol Reviews Rating Popularity
Rituxan Rx C N Add review Add

Generic name: rituximab systemic

Drug class: antirheumatics, CD20 monoclonal antibodies

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

 
rituximab Rx C N 1 review
2.0

Generic name: rituximab systemic

Brand name:  Rituxan

Drug class: antirheumatics, CD20 monoclonal antibodies

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

 
Showing all

Legend

Off Label This medication may not be approved by the FDA for the treatment of this condition.
Prescription Only / Over the Counter
Rx Prescription Only
OTC Over the Counter
Rx/OTC Prescription or Over the Counter
Pregnancy
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act Schedule
N The drug is not subject to the Controlled Substances Act.
1 The drug has a high potential for abuse. The drug has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use of the drug under medical supervision.
2 The drug has a high potential for abuse. The drug has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse of the drug may lead to severe psychological or physical dependence.
3 The drug has a potential for abuse less than the drugs in schedules 1 and 2. The drug has a currently accepted medical use in treatment in the United States. Abuse of the drug may lead to moderate or low physical dependence or high psychological dependence.
4 The drug has a low potential for abuse relative to the drugs in schedule 3. The drug has a currently accepted medical use in treatment in the United States. Abuse of the drug may lead to limited physical dependence or psychological dependence relative to the drugs in schedule 3.
5 The drug has a low potential for abuse relative to the drugs in schedule 4. The drug has a currently accepted medical use in treatment in the United States. Abuse of the drug may lead to limited physical dependence or psychological dependence relative to the drugs in schedule 4.
Alcohol
X Interacts with Alcohol.

Synonym(s): MPA

Browse Drugs by Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hide